NOL7: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Target Name: NOL7

NCBI ID: G51406

NOL7

NOL7: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Introduction

Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow, where blood cells are produced. It is characterized by the uncontrolled proliferation of white blood cells called leukemia cells, which results in a buildup of waste products in the bone marrow and the development of various signs and symptoms. The most common form of CML is B-cell chronic myeloid leukemia (BCML), which accounts for approximately 90% of all CML cases.

Nucleolar protein 7 (NOL7) is a protein that is expressed in various tissues, including the bone marrow, and has been implicated in the development and progression of cancer. NOL7 has been identified as a potential drug target and biomarker for BCML. In this article , we will discuss the biology of NOL7, its potential as a drug target, and its potential as a biomarker for BCML.

Biochemistry and gene expression

Nucleolar protein 7 (NOL7) is a 21-kDa protein that is expressed in various tissues, including the bone marrow, where it is involved in the regulation of cell growth and differentiation. NOL7 is a member of the nucleolar complex, which is a protein complex that is responsible for the synthesis and assembly of nuclear proteins in the cytoplasm of the cell.

NOL7 has been shown to play a role in the regulation of cell cycle progression in various cell types. In addition, NOL7 has been shown to be involved in the regulation of apoptosis, which is the process by which cells undergo programmed cell death.

Mutations in NOL7 have been observed in various cancer types, including BCML. These mutations have been shown to alter the structure and function of NOL7 and to contribute to the development and progression of cancer.

Potential drug target

NOL7 has been identified as a potential drug target for BCML due to its involvement in the regulation of cell cycle progression and apoptosis. NOL7 has been shown to play a role in the regulation of the B-cell receptor (BCR), which is a protein that is involved in the development and maintenance of B-cell identity and proliferation.

In addition, NOL7 has been shown to play a role in the regulation of the tyrosine kinase (TK) signaling pathway, which is involved in the regulation of cell growth and differentiation. Activation of the TK signaling pathway has been shown to promote the growth and proliferation of BCML cells.

Biomarker potential

NOL7 has also been identified as a potential biomarker for BCML due to its expression in various tissues, including the bone marrow, where it is involved in the regulation of cell growth and differentiation. The levels of NOL7 have been shown to be altered in various types of cancer, including BCML.

In addition, NOL7 has been shown to play a role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. Elevated levels of NOL7 have been observed in BCML cells, which may indicate an increased sensitivity to apoptosis-inducing treatments.

Conclusion

Nucleolar protein 7 (NOL7) has been shown to play a role in the regulation of cell cycle progression and apoptosis in various cell types, including the bone marrow, where it is involved in the development and progression of BCML. Its potential as a drug target and biomarker for BCML makes it an attractive target for further research in this field.

The identification of NOL7 as a potential drug target and biomarker for BCML has the potential to improve our understanding of the biology of this disease and to develop new treatments for BCML. Further research is needed to

Protein Name: Nucleolar Protein 7

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome

The "NOL7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NOL7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets